ALX Oncology Holdings Inc. has announced the initiation of its Phase 1 clinical development program for ALX2004, following clearance of its Investigational New Drug $(IND.AU)$ application by the U.S. Food and Drug Administration in April 2025. ALX2004, a novel EGFR-targeted antibody-drug conjugate, is set to enter Phase 1 trials in mid-2025. The trial will focus on dose escalation in patients with EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma. Initial safety data from the study is anticipated in the first half of 2026. ALX Oncology will provide further details on its clinical development plans and preclinical data in a webcast event. For more information, visit ALX Oncology's website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。